Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Open accessAbstract
Purpose of review One begins to see improvement in glycemic measures and triglycerides with small amounts of weight loss, but with greater levels of weight loss there is even greater improvement. In fact, the relationship between weight loss and glycemia is one that is very close.Recent findings This is fortunate for diabetes prevention; it takes only small amounts of weight loss to prevent progression to type 2 diabetes from impaired glucose tolerance, and after the 10 kg of weight loss, one cannot demonstrate much additional improvement in risk reduction. Modest weight loss (5 to 10%) is also associated with improvement in systolic and diastolic blood pressure and HDL cholesterol. With all these risk factors, more weight loss produces more improvement. Further, for patients with higher BMI levels (>40 kg/m 2), the ability to lose the same proportion of weight with lifestyle intervention is equal to that of those with lower BMI levels, and there is equal benefit in terms of risk factor improvement with modest weight loss. For some comorbid conditions, more weight loss is needed-10 to 15%-to translate into clinical improvement. This is true with obstructive sleep apnea and non-alcoholic steatotic hepatitis. There is a graded improvement in improvements in measures of quality of life, depression, mobility, sexual dysfunction, and urinary stress incontinence, whereby improvements are demonstrable with modest weight loss (5-10%) and with further weight loss there are further improvements. For polycystic ovarian syndrome and infertility, modest weight loss (beginning at 2-5%) can bring improvements in menstrual irregularities and fertility. Moderate weight loss (5-10%) has been shown to be associated with reduced health care costs. Reduction in mortality may take more than 10% weight loss, although definitive studies have not been done to demonstrate that weight loss per se is associated with mortality reduction. Clinicians in medical weight management should bear in mind that the target should be health improvement rather than a number on the scale. The individual patient's targeted health goal should be assessed for response rather than a prescribed percentage weight loss.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Weight reduction achieved with GLP-1s can improve symptoms of obstructive sleep apnea, a common obesity-related condition.
“Conversely, weight reduction achieved with GLP‐1s can improve symptoms of obstructive sleep apnea, a common obesity‐related condition [184].”
From Nutritional priorities to support <scp>GLP</scp> ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [184]
The section on obstructive sleep apnea reports that weight loss improved apnea symptoms and remission rates, with about 10% or more weight loss recommended to affect clinical symptoms. Its evidence comes from an intensive lifestyle intervention, not GLP-1 treatment, so it does not establish the GLP-1-specific part of the claim. No page number is available in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredThese improvements could translate over time to a decreased risk of metabolic syndrome, cardiovascular disease, hypertension, type 2 diabetes, non-alcoholic fatty liver disease, and chronic renal disease, ultimately leading to a marked improvement in health-related quality of life for overweight or obese people.
“These improvements could translate over time to a decreased risk of metabolic syndrome, cardiovascular disease, hypertension, T2D, non-alcoholic fatty liver disease (NAFLD), and chronic renal disease, ultimately leading to a marked improvement in the health-related quality of life for overweight or obese people [31, 38].”
From Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial (2024) · cites this paper as [31]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredAmong people with obesity, 5% to 10% weight loss improves systolic blood pressure by about 3 mm Hg for those with hypertension.
“Among people with obesity, 5% to 10% weight loss improves systolic blood pressure by about 3 mm Hg for those with hypertension, and may decrease hemoglobin A1c by 0.6% to 1% for those with type 2 diabetes.”
From Obesity Management in Adults (2023) · cites this paper as [8]
The Abstract says 5–10% weight loss is associated with improved systolic blood pressure, and section 3 reports that systolic blood pressure improves with weight loss. Neither passage gives an approximately 3 mm Hg reduction specifically for people with hypertension. Page numbers are not available in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredA 5% weight loss may reduce systolic and diastolic blood pressure by 3 mm Hg and 2 mm Hg among those with hypertension, respectively.
“A 5% weight loss may reduce systolic and diastolic blood pressure by 3 mm Hg and 2 mm Hg among those with hypertension, respectively;”
From Obesity Management in Adults (2023) · cites this paper as [8]
The section on cardiovascular disease risk factors reports that systolic blood pressure improves with ≥2% to <5% weight loss and diastolic blood pressure with ≥5% to <10% weight loss. It does not give the claimed 3 mm Hg and 2 mm Hg reductions or specify that those estimates apply to people with hypertension. No page number is available in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredReaching a 15% weight loss may further decrease the risk of heart attacks and strokes and enhance overall quality of life.
“Reaching a 15% weight loss may further decrease the risk of heart attacks and strokes and enhance overall quality of life [42].”
From The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials (2025) · cites this paper as [42]
The ‘Weight Loss and Mortality Reduction’ section reports that losing at least 10% of body weight was associated with fewer major cardiovascular events in a post hoc analysis, and section 8 describes graded improvements in quality of life with weight loss. The paper does not establish an additional reduction specifically at 15% or report separate heart-attack and stroke risks. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Among people with obesity and type 2 diabetes, 5% to 10% weight loss may decrease hemoglobin A1c by 0.6% to 1%.
“and may decrease hemoglobin A1c by 0.6% to 1% for those with type 2 diabetes.”
From Obesity Management in Adults (2023) · cites this paper as [8]
The section “Modest and moderate weight loss in established type 2 diabetes” (page not available in our copy) reports that hemoglobin A1c improves with weight loss in people with type 2 diabetes, including the 5%–10% weight-loss category. It does not give the claimed 0.6%–1% decrease in A1c. (LLM, conf=0.88)
Experimental — accuracy not yet measuredA 5% to 10% weight loss may decrease hemoglobin A1c by 0.6% to 1.0% among those with type 2 diabetes and can increase high-density lipoprotein cholesterol level by 2 mg/dL.
“5% to 10% loss may decrease hemoglobin A1c by 0.6% to 1.0% among those with type 2 diabetes and can increase high-density lipoprotein cholesterol level by 2 mg/dL [0.052 mmol/L].5,8”
From Obesity Management in Adults (2023) · cites this paper as [8]
In “Modest and moderate weight loss in established type 2 diabetes,” the paper reports improved hemoglobin A1c with weight loss in people with type 2 diabetes. In the cardiovascular risk factors section, it reports that HDL cholesterol improves beginning at 5% to 10% weight loss. Neither section gives the claimed 0.6%–1.0% A1c decrease or 2 mg/dL HDL increase; page numbers were not available in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredA 10% to 15% weight loss may be required to improve other conditions such as hepatic steatosis and obstructive sleep apnea.
“A 10% to 15% loss may be required to improve other conditions (eg, hepatic steatosis, obstructive sleep apnea).8”
From Obesity Management in Adults (2023) · cites this paper as [8]
The obstructive sleep apnea section says 10% or more weight loss should be the goal for improving clinical symptoms. But the hepatic steatosis and NASH section reports a reduction in liver fat at 5% weight loss; it is improvement in NASH activity scores that may take 10% or more. The claim conflates hepatic steatosis with NASH on that point. Page numbers are not available in the supplied copy. (LLM, conf=0.87)
Experimental — accuracy not yet measuredWeight loss improves glucose, lipids, blood pressure, and obesity-related comorbidities.
“Weight loss improves glucose, lipids, blood pressure, and obesity-related comorbidities,4,5,8”
From Obesity Management in Adults (2023) · cites this paper as [8]
A weight reduction of between 5% and 10% can improve insulin sensitivity, lower blood pressure and triglycerides, and alleviate joint stress.
“A weight reduction of between 5% and 10% can improve insulin sensitivity, lower blood pressure and triglycerides, and alleviate joint stress [42].”
From The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials (2025) · cites this paper as [42]
Achieving weight loss of 10% or more is linked to additional health benefits, including enhanced glycemic control, decreased need for diabetic medications, and reduced risk of cardiovascular events.
“Achieving weight loss of 10% or more is linked to additional health benefits, including enhanced glycemic control, decreased need for diabetic medications, and reduced risk of cardiovascular events [23].”
Weight loss beyond 15% is associated with lower rates of all-cause mortality among those who undergo bariatric surgery and greater weight loss is associated with improved quality of life.
“Weight loss beyond 15% is associated with lower rates of all-cause mortality among those who undergo bariatric surgery and greater weight loss is associated with improved quality of life.8”
From Obesity Management in Adults (2023) · cites this paper as [8]
A 5% weight loss is recommended to improve comorbidities.
“This is below the recommended 5% weight loss needed to improve comorbidities39.”
From Nutritional and exercise interventions in individuals with sarcopenic obesity around retirement age: a systematic review and meta-analysis (2023) · cites this paper as [39]
Weight reduction achieved with GLP-1s can improve symptoms of obstructive sleep apnea, a common obesity-related condition.
“Conversely, weight reduction achieved with GLP-1s can improve symptoms of obstructive sleep apnea, a common obesity-related condition [176].”
Reducing 5 to 10% of usual weight can improve reproductive function in women with PCOS.
“Reducing 5 to 10% of the usual weight can improve reproductive function [15].”
From Ketogenic Diet as Medical Prescription in Women with Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [15]
Weight reduction achieved with GLP-1s can improve symptoms of obstructive sleep apnea, a common obesity-related condition.
“Conversely, weight reduction achieved with GLP-1s can improve symptoms of obstructive sleep apnea, a common obesity-related condition [184].”
Weight loss exceeding 10% can additionally improve cancer risk, fertility, and health-care costs, while further improving cardiometabolic outcomes in younger adults.
“whilst weight loss exceeding 10% can additionally improve cancer risk, fertility, and health-care costs, while further improving cardiometabolic outcomes [43, 44].”
From Obesity pharmacotherapy in older adults: a narrative review of evidence (2025) · cites this paper as [44]
Weight loss of 5-10% total body weight can improve physical function and cardiometabolic risk factors such as blood pressure and lipid profile in younger adults.
“Weight loss of 5–10% total body weight can improve physical function and such cardiometabolic risk factors as blood pressure and lipid profile, whilst weight loss exceeding 10% can additionally improve cancer risk, fertility, and health-care costs, while further improving cardiometabolic outcomes [43, 44].”
From Obesity pharmacotherapy in older adults: a narrative review of evidence (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · see citing works
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · see citing works
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · see citing works
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · see citing works
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908 · see citing works
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · see citing works
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · see citing works
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344 · see citing works
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · see citing works
Messier, S. P., Loeser, R. F., Miller, G. D., Morgan, T. M., Rejeski, W. J., Sevick, M. A., Ettinger, W. H., Pahor, M., & Williamson, J. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20256 · Cited by 1,065 · see citing works
Kiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921 · see citing works
Magkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886 · see citing works
Messier, S. P., Mihalko, S. L., Legault, C., Miller, G. D., Nicklas, B. J., DeVita, P., Beavers, D. P., Hunter, D. J., Lyles, M. F., Eckstein, F., et al. (2013) · JAMA · doi:10.1001/jama.2013.277669 · Cited by 873 · see citing works
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738 · see citing works
Weight loss reduces knee‐joint loads in overweight and obese older adults with knee osteoarthritis
Messier, S. P., Gutekunst, D. J., Davis, C., & DeVita, P. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21139 · Cited by 576 · see citing works
Foster, G. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.266 · Cited by 538 · see citing works
Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?
Williamson, D. A., Bray, G. A., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21358 · Cited by 367 · see citing works
Self-citationLazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367 · see citing works
Crosignani, P. G. (2003) · Human Reproduction · doi:10.1093/humrep/deg367 · Cited by 359 · see citing works
Does Obesity Increase the Risk of Miscarriage in Spontaneous Conception: A Systematic Review
Boots, C. E., & Stephenson, M. D. (2011) · Seminars in Reproductive Medicine · doi:10.1055/s-0031-1293204 · Cited by 345 · see citing works
Lifestyle change and mobility in obese adults with type 2 diabetes
Rejeski, W. J., Ip, E. H., Bertoni, A. G., Bray, G. A., Evans, G., Gregg, E. W., & Zhang, Q. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110294 · Cited by 301 · see citing works
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K. Z., Pessah‐Pollack, R., & Plodkowski, R. A. (2016) · Endocrine Practice · doi:10.4158/ep161356.esgl · Cited by 287 · see citing works
The Relationship between Health‐Related Quality of Life and Weight Loss
Kolotkin, R. L., Crosby, R. D., Williams, G. R., Hartley, G. G., & Nicol, S. E. (2001) · Obesity Research · doi:10.1038/oby.2001.73 · Cited by 280 · see citing works
Huber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269 · see citing works
Williamson, D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.544 · Cited by 244 · see citing works
Kuna, S. T., Reboussin, D. M., Borradaile, K. E., Sanders, M. H., Millman, R. P., Zammit, G., Newman, A. B., Wadden, T. A., Jakicic, J. M., Wing, R. R., et al. (2013) · Sleep · doi:10.5665/sleep.2618 · Cited by 231 · see citing works
Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes
Unick, J. L., Beavers, D. P., Jakicic, J. M., Kitabchi, A. E., Knowler, W. C., Wadden, T. A., & Wing, R. R. (2011) · Diabetes Care · doi:10.2337/dc11-0874 · Cited by 219 · see citing works
Wing, R. R., Rosen, R. C., Fava, J. L., Bahnson, J., Brancati, F., Gendrano, I. N. C., Kitabchi, A., Schneider, S. H., & Wadden, T. A. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01458.x · Cited by 180 · see citing works
Espeland, M. A., Glick, H. A., Bertoni, A., Brancati, F. L., Bray, G. A., Clark, J. M., Curtis, J. M., Egan, C., Evans, M., Foreyt, J. P., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0093 · Cited by 174 · see citing works
Self-citationThe clinical biochemistry of obesity.
Sikaris, K. A. (2004) · PubMed Central · Cited by 158 · see citing works
Bays, H. E. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000093 · Cited by 142 · see citing works
Ryan, D. H., & Heaner, M. K. (2014) · Obesity · doi:10.1002/oby.20819 · Cited by 127 · see citing works
Self-citationFaulconbridge, L. F., Wadden, T. A., Rubin, R. R., Wing, R. R., Walkup, M. P., Fabricatore, A. N., Coday, M., Van Dorsten, B., Mount, D. L., Ewing, L. J., et al. (2012) · Obesity · doi:10.1038/oby.2011.315 · Cited by 117 · see citing works
Phelan, S., Kanaya, A. M., Subak, L. L., Hogan, P. E., Espeland, M. A., Wing, R. R., Burgio, K. L., DiLillo, V., Gorin, A. A., West, D. S., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2011.10.139 · Cited by 107 · see citing works
The Intensive Diet and Exercise for Arthritis (IDEA) trial: 18-month radiographic and MRI outcomes
Hunter, D. J., Beavers, D. P., Eckstein, F., et al. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.03.034 · Cited by 85 · see citing works
Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes
Wing, R. R., Bond, D. S., Gendrano, I. N., Wadden, T. A., Bahnson, J. L., Lewis, C. E., Brancati, F. L., Schneider, S., Kitabchi, A. E., Dorsten, B. V., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0315 · Cited by 75 · see citing works
Are Astrocytes the Pressure-Reservoirs of Lactate in the Brain?
Kasparov, S. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.11.001 · Cited by 54 · see citing works
Breyer, B. N., Phelan, S., Hogan, P. E., Rosen, R. C., Kitabchi, A. E., Wing, R. R., & Brown, J. S. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.02.036 · Cited by 53 · see citing works
Pharmacologic sex hormones in pregnancy in relation to offspring obesity
Jensen, E. T., & Longnecker, M. P. (2014) · Obesity · doi:10.1002/oby.20778 · Cited by 44 · see citing works
Can an Intensive Diet and Exercise Program Prevent Knee Pain Among Overweight Adults at High Risk?
White, D. K., Neogi, T., Rejeski, W. J., Walkup, M. P., Lewis, C. E., Nevitt, M. C., Foy, C. G., & Felson, D. T. (2015) · Arthritis Care & Research · doi:10.1002/acr.22544 · Cited by 29 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Jensen MD Ryan DH Donato KA 2014 Guidelines 2013 for managing overweight and obesity in adults Obesity 22 S1 S410 These guidelines are based on a systematic evidence review around 5 critical questions (benefits of weight loss, risks of excess body weight, best diet for weight loss, weight loss with comprehensive lifestyle intervention and role of bariatric surgery). 24961822
- [17]Messier SP Gutekunst DJ Davis C DeVita P Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis ARTHRITIS & RHEUMATISM 2004 52 7 2026 2032 15986358
Cited by
Sorted by citations
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · see citing works
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · see citing works
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · see citing works
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 748 · see citing works
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.025 · Cited by 608 · see citing works
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0406 · Cited by 510 · see citing works
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02996-7 · Cited by 347 · see citing works
Self-citationAGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347 · see citing works
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · see citing works
Semaglutide for the treatment of overweight and obesity: A review
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14863 · Cited by 265 · see citing works
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238 · see citing works
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182 · see citing works
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184 · see citing works
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2511774 · Cited by 189 · see citing works
Seimon, R. V., Wild-Taylor, A. L., Keating, S. E., McClintock, S., Harper, C., Gibson, A. A., Johnson, N. A., Fernando, H. A., Markovic, T. P., Center, J. R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13733 · Cited by 152 · see citing works
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154 · see citing works
“Conversely, weight reduction achieved with GLP-1s can improve D. Mozaffarian et al. symptoms of obstructive sleep apnea, a common obesity-related condition [176].”
Nutritional considerations with antiobesity medications
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., et al. (2024) · Obesity · doi:10.1002/oby.24067 · Cited by 134 · see citing works
Zhao, L., Cheng, Z., Lu, Y., Liu, M., Chen, H., Zhang, M., Wang, R., Yuan, Y., & Li, X. (2024) · JAMA · doi:10.1001/jama.2024.9217 · Cited by 132 · see citing works
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143 · see citing works
Tirzepatide: A Systematic Update
Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314631 · Cited by 118 · see citing works
Machado, A. M., Guimarães, N. S., Bocardi, V. B., da Silva, T. P. R., Carmo, A. S. D., Menezes, M. C. D., & Duarte, C. K. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.03.020 · Cited by 109 · see citing works
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102 · see citing works
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Kittleson, M. M., Benjamin, E. J., Blumer, V., Harrington, J., Januzzi, J. L., McMurray, J. J. V., & Vest, A. R. (2025) · JACC · doi:10.1016/j.jacc.2025.05.008 · Cited by 79 · see citing works
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Pedersen, S. D., Manjoo, P., Dash, S., Jain, A., Pearce, N., & Poddar, M. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.250502 · Cited by 78 · see citing works
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., Butsch, W. S., & Rothberg, M. B. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.33326 · Cited by 71 · see citing works
Rosenfeld, R. M., Kelly, J. H., Agarwal, M., Aspry, K., Barnett, T., Davis, B. C., Fields, D., Gaillard, T., Gulati, M., Guthrie, G. E., et al. (2022) · American Journal of Lifestyle Medicine · doi:10.1177/15598276221087624 · Cited by 71 · see citing works
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68 · see citing works
Investigation of the long-term sustainability of changes in appetite after weight loss
Nymo, S., Coutinho, Sr., Eknes, P., Vestbostad, I., Rehfeld, J., Truby, H., Kulseng, B., & Martins, C. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0119-9 · Cited by 68 · see citing works
Eglseer, D., Traxler, M., Schoufour, J. D., Weijs, P. J. M., Voortman, T., Boirie, Y., Cruz-Jentoft, A. J., Reiter, L., Bauer, S., for the SO-NUTS Consortium, et al. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad007 · Cited by 68 · see citing works
Ryan, D. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21033 · Cited by 67 · see citing works
Self-citationGilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65 · see citing works
Ketogenic Diet as Medical Prescription in Women with Polycystic Ovary Syndrome (PCOS)
Barrea, L., Verde, L., Camajani, E., Cernea, S., Frias-Toral, E., Lamabadusuriya, D., Ceriani, F., Savastano, S., Colao, A., & Muscogiuri, G. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00456-1 · Cited by 62 · see citing works
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59 · see citing works
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58 · see citing works
Małecki, M. T., Batterham, R. L., Sattar, N., Levine, J. A., Rodríguez, Á., Bergman, B. K., Wang, H., Ghimpeteanu, G., & Lee, C. J. (2023) · Diabetes Care · doi:10.2337/dc23-1135 · Cited by 52 · see citing works
Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024) · Endocrine · doi:10.1007/s12020-024-03896-z · Cited by 55 · see citing works
“…translate over time to a decreased risk of metabolic syndrome, cardiovascular disease, hypertension, T2D, non-alcoholic fatty liver disease (NAFLD), and chronic renal disease, ultimately leading to a marked improvement in the health-related quality of life for overweight or obese people [31, 38].”
BackgroundGeorgoulis, M., Yiannakouris, N., Kechribari, I., Lamprou, K., Perraki, E., Vagiakis, E., & Kontogianni, M. D. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.9834 · Cited by 56 · see citing works
Obesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51 · see citing works
Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15269 · Cited by 44 · see citing works
Weight loss in a digital app-based diabetes prevention program powered by artificial intelligence.
Graham, S. A., Pitter, V., Hori, J. H., Stein, N., & Branch, O. H. (2022) · DIGITAL HEALTH · doi:10.1177/20552076221130619 · Cited by 43 · see citing works
Brellenthin, A. G., Lee, D.-C., Bennie, J. A., Sui, X., & Blair, S. N. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003687 · Cited by 41 · see citing works
Ruseva, A., Michalak, W., Zhao, Z., Fabricatore, A., Hartaigh, B. Ó., & Umashanker, D. (2024) · Obesity Science & Practice · doi:10.1002/osp4.737 · Cited by 40 · see citing works
Moravcová, K., Karbanová, M., Bretschneider, M. P., Sovová, M., Ožana, J., & Sovová, E. (2022) · Nutrients · doi:10.3390/nu14102005 · Cited by 37 · see citing works
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39 · see citing works
le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15148 · Cited by 36 · see citing works
Glucagon receptor signaling regulates weight loss via central KLB receptor complexes
Nason, S. R., Antipenko, J., Presedo, N., Cunningham, S. E., Pierre, T. H., Kim, T., Paul, J. R., Holleman, C., Young, M. E., Gamble, K. L., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141323 · Cited by 34 · see citing works
Digital Health Solutions for Weight Loss and Obesity: A Narrative Review
Irvin, L., Madden, L. A., Marshall, P., & Vince, R. V. (2023) · Nutrients · doi:10.3390/nu15081858 · Cited by 34 · see citing works
Efficacy and safety of prolonged water fasting: A narrative review of human trials
Ezpeleta, M., Cienfuegos, S., Lin, S., Pavlou, V., Gabel, K., & Varady, K. A. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuad081 · Cited by 32 · see citing works
Xie, Y., Zhou, K., Shang, Z., Bao, D., & Zhou, J. (2024) · Nutrients · doi:10.3390/nu16193390 · Cited by 29 · see citing works
“(1) Supplement S1: Table S1 Subgroup analysis results; Figure S1: Certainty of the evidence; (2) Supplement S2: Search query history for Seven electronic databases; and (3) Supplement S3: Body Fat Percentage Calculation.”
BackgroundMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28 · see citing works
Wang, Y.-Y., Tian, F., Qian, X.-L., Ying, H.-M., & Zhou, Z.-F. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1439473 · Cited by 28 · see citing works
GIUSTI, E. M., SPATOLA, C. A., BRUNANI, A., KUMBHARE, D., ORAL, A., ILIEVA, E., KIEKENS, C., PIETRABISSA, G., MANZONI, G. M., IMAMURA, M., et al. (2020) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.20.06232-2 · Cited by 25 · see citing works
Johnson, H., Huang, D., Liu, V., Ammouri, M. A., Jacobs, C., & El-Osta, A. (2025) · Journal of Medical Internet Research · doi:10.2196/69466 · Cited by 24 · see citing works
“Achieving weight loss of 10% or more is linked to additional health benefits, including enhanced glycemic control, decreased need for diabetic medications, and reduced risk of cardiovascular events [23].”
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050668 · Cited by 19 · see citing works
Examining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18 · see citing works
Obesity drug shortages are symptomatic of wider malaise
Sumithran, P., Finucane, F. M., & Cohen, R. V. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01963-3 · Cited by 16 · see citing works
Petersen, J., Merrild, C., Lund, J., Holm, S., & Clemmensen, C. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102027 · Cited by 13 · see citing works
Schultes, B., Timper, K., Cavadini, G., Rüh, J., & Gerber, P. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15403 · Cited by 13 · see citing works
Khawaji, A., A. Jaly, A., A. Bakri, H., Ravi, R., Hattan, A., Khawaji, A., & Najmi, W. (2025) · Journal of Obesity · doi:10.1155/jobe/3442754 · Cited by 13 · see citing works
Ard, J. D., Neeland, I. J., Rothberg, A. E., Chilton, R. J., de Luis, D., Cohen, S. S., & Johansen, O. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15392 · Cited by 12 · see citing works
Richards, R., Wren, G., & Whitman, M. (2024) · JMIR Diabetes · doi:10.2196/52987 · Cited by 9 · see citing works
Naude, J., Zentner, A., Suresh, P., Bittman, J., & Khan, N. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01526-2 · Cited by 13 · see citing works
RetractedZakaria, H., Alshehhi, S., Caccelli, M., Ozkan, C., Kattan, J., Jafaar, Z., Laborte, R., Aleabova, S., Almarzooqi, N., Hashemi, A., et al. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100283 · Cited by 11 · see citing works
Richards, R., Wren, G. M., Campion, P., & Whitman, M. (2023) · JMIR Formative Research · doi:10.2196/53619 · Cited by 9 · see citing works
Weight Trajectory Impacts Risk for 10 Distinct Cardiometabolic Diseases
Swartz, A. Z., Wood, K., Farber-Eger, E., Petty, A., & Silver, H. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf348 · Cited by 10 · see citing works
Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0469 · Cited by 10 · see citing works
Liao, Y.-N., Chen, H.-Y., Yang, C.-W., Lee, P.-W., Hsu, C.-Y., Huang, Y.-T., & Yang, T.-H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.978814 · Cited by 7 · see citing works
Giusti, E. M., Spatola, C. A. M., Brunani, A., Kumbhare, D., Oral, A., Ilieva, E., Kiekens, C., Pietrabissa, G., Manzoni, G. M., Imamura, M., et al. (2020) · The Journal of the International Society of Physical and Rehabilitation Medicine · doi:10.4103/jisprm.jisprm_6_20 · Cited by 2 · see citing works
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2 · see citing works
- Authors
- Ryan, D. H., & Yockey, S. R.
- Affiliations
- Pennington Biomedical Research Center (US)
- Louisiana State University (US)
- Corresponding author
- Ryan, Donna H.
- ORCID
- Ryan, Donna H.
- Venue
- Current Obesity Reports
- Published
- 2017-04-28
- Volume
- 6
- Issue
- 2
- Pages
- 187-194
- ISSN
- 2162-4968 (ISSN-L)
- PMC
- PMC5497590
- OpenAlex
- W2609075277
- Cited by
- 831
- References
- 40
- Citations by year
- 2026: 99 · 2025: 173 · 2024: 152 · 2023: 154 · 2022: 105 · 2021: 67 · 2020: 43 · 2019: 23 · 2018: 11 · 2017: 3
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Obesity Reports (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (U54GM104940)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- weight loss, obesity, comorbidities, type 2 diabetes prevention, impaired glucose tolerance, glycemic control, triglycerides, blood pressure, HDL cholesterol, body mass index, lifestyle intervention, obstructive sleep apnea, nonalcoholic steatohepatitis, polycystic ovary syndrome, infertility, quality of life, health care costs, mortality reduction
- MeSH terms
- Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Female, Health Status, Humans, Hypertension, Lipids, Obesity, Polycystic Ovary Syndrome, Quality of Life, Risk Factors, Sleep, Biomarkers, Weight Loss, Comorbidity, Treatment Outcome, Practice Guidelines as Topic, Sleep Apnea, Obstructive, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
